Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Strong KesimptaⓇ launch in a suppressed market*
US MS market* growth still suppressed
NBRX
34k
30k
28k
27k.
23k'
Q1/21
Q2/21
Q3/21
Q4/21
Q1/22
Sales evolution
1 GROWTH
CE Z
K Kesimpta L
Accelerating launch momentum
"
About 20k patients treated, >60% naive or first switch4
US: strong growth despite suppressed market dynamics
Ex-US: approved in 68 countries
Strengthening differentiation and benefit/ risk profile
"
Up to 4 years data show continued reduced risk of disability worsening and stable IgG
levels (ASCLEPIOS/ALITHIOS)1,2
Majority of Kesimpta treated patients can mount a robust immune response after
COVID-19 vaccination; may be distinct amongst B cell treatments³
USD m
Ex-US
US
195
■
147
109
66
50
Q1/21
Q2/21
Q3/21
Q4/21
Q1/22
*Refers to dynamic market. NBRX - New to brand Prescription IgG - Immunoglobulin G mRNA-messenger Ribonucleic Acid. See References at end of this presentation.
12 Investor Relations | Q1 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation